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Letter to the editor
Lack of Zika virus antibody response in conﬁrmed patients in non-endemic countries
Zika virus (ZIKV) has spread in the last 2 years throughout America and South-Eastern Asia causing a widespread epidemic [1]. Detection of ZIKV
RNA in body ﬂuids conﬁrms ZIKV infection, however ZIKV antibody testing is much more complex due to possible cross-reactivity with closely
related ﬂaviviruses [2].
From December 2015 to February 2017, 401 patients from eight reference laboratories in the Czech Republic, Israel, Italy, the Netherlands,
Romania, Slovenia, and the United Kingdom had been conﬁrmed for ZIKV infection by detection of ZIKV RNA in body ﬂuids [2–4] (Table 1). Of these
401 patients, 148 were negative for ZIKV directed against IgM and IgG in serum collected at the time of PCR-positivity as tested by ELISA (7
laboratories, Euroimmun, Lübeck, Germany) or IFA and ELISA (2 laboratories, Euroimmun, Lübeck, Germany). For 80 of these 148 seronegative
conﬁrmed patients a second, follow-up serum sample was available. Altogether, 5 of these 80 patients remained without seroconversion in con-
secutive samples (Table 2) for ZIKV antibodies tested by ELISA and virus neutralization (VNT) (Table 2). The acute samples of these 5 patients were
re-extracted and retested from original material which conﬁrmed the presence of ZIKV RNA. Material from patients 1 and 2 were sequenced [5].
Ideally, each of the samples from the 5 patients would also have been tested in at least one of the other laboratories, but because of insuﬃcient
clinical material, this wasn’t possible. Most importantly, none of the sero-negative patients had any indication of immune-deﬁciency. Two patients
were pregnant.
One explanation for the lack of detection of ZIKV IgM or IgG antibodies in 5 of our patients is low sensitivity of the assays. Indeed, a few studies
have previously demonstrated low sensitivity of the Euroimmun NS1 ELISA [6–9]. However, since neutralization is widely accepted as the gold
standard test for arboviral infections and unlike the NS1 ELISA, neutralization primarily recognizes antibodies against surface proteins, the prob-
ability that both tests failed to detect ZIKV antibodies is low. Another explanation is that production of ZIKV antibodies was suppressed in these cases
maybe due to a previous ﬂavivirus infection which might suppress ZIKV immune response including the production of neutralizing antibodies
(original antigenic sin [10,11]).
In conclusion, our results show absence of ZIKV speciﬁc antibodies using routine serological assays in 5 of 80 of convalescent sera from PCR
conﬁrmed ZIKV cases in returning travelers. This may suggest signiﬁcant under-diagnosis of ZIKV infections when diagnosis relies on serology alone.
This is especially of importance in cases where congenital Zika syndrome might be involved such as diagnosis of pregnant women or males with
pregnant partners. As serum of pregnant women, whole blood and semen provide a longer window of detection for PCR [12–15], these samples
should be tested by RT-PCR alongside serology. Relating the absence of detectable ZIKV immune responses to the absence/severity of clinical
symptoms and previous ﬂavivirus antigen exposure in larger cohort studies might provide insight into the groups at risk for such under-diagnosis.
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